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Obesity is a leading cause of death worldwide because of its
associated inflammatory disorders such as hypertension,
cardiovascular and kidney diseases, dyslipidemia, glucose
intolerance, and certain types of cancer. Adipose tissue
expresses all components of the renin–angiotensin system
necessary to generate angiotensin (Ang) peptides for local
function. The angiotensin type 1 (AT1) and type 2 (AT2)
receptors mediate the effect of Ang II and recent studies have
shown that both receptors may modulate fat mass expansion
through upregulation of adipose tissue lipogenesis (AT2) and
downregulation of lipolysis (AT1). Thus, both receptors may
have synergistic and additive effects to promote the storage
of lipid in adipose tissue in response to the nutrient
environment. The production of angiotensinogen (AGT) by
adipose tissue in rodents also contributes to one third of the
circulating AGT levels. Increased adipose tissue AGT
production in the obese state may be responsible in part for
the metabolic and inflammatory disorders associated with
obesity. This supports the notion that besides the traditional
role of Ang II produced by the liver in the control of blood
pressure, Ang II produced by the adipose tissue may more
accurately reflect the role of this hormone in the regulation
of fat mass and associated disorders.
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Angiotensinogen (AGT), the precursor of the renin–angio-
tensin system (RAS) is converted through an enzymatic
cascade to angiotensin I and angiotensin II (Ang II) by the
actions of renin and angiotensin-converting enzyme (ACE),
respectively. Ang(1–7) is formed from Ang I and Ang II by
ACE2 (Figure 1). The production of Ang II is linked to
hypertension and several inflammatory diseases including
cardiovascular and kidney diseases, dyslipidemia and glucose
intolerance (also known as the metabolic syndrome). AGT is
highly expressed in adipose tissue and is constitutively
secreted by mature adipocytes from separate adipose depots
in animal models and in humans.1 In rodents, this
production may contribute as much as 30% of circulating
AGT levels in vivo,2 arguing for a paracrine role of adipose
AGT and consistent with the new view of adipose tissue as an
endocrine organ. Adipose AGT may also have autocrine
effects given that adipose tissue expresses all the components
of the RAS, including renin, ACE, and ACE2. This permits
local production of Ang II and other angiotensin peptides in
adipose tissue.3,4 Both adipocytes and preadipocytes express
angiotensin receptors including Ang II receptors type 1 (AT1)
and type 2 (AT2) as well as Ang IV and Ang(1–7) receptors
(MasR).5 This review will summarize the autocrine role
of the adipose RAS (aRAS) as well as the critical paracrine
role of this system in regulating lipid and glucose
homeostasis with consequences on metabolic and inflamma-
tory diseases.
RAS, BODY WEIGHT, AND ENERGY HOMEOSTASIS
RAS and accumulation of body fat
Increased local formation of Ang II in adipose tissue has
been originally observed in genetically or diet-induced obese
rodents and in humans,6–8 and generation of transgenic mice
overexpressing AGT in adipose tissue leads to the develop-
ment of obesity.2 This last observation has been a major
contributing factor in favor of Ang II as an endocrine effector
in obesity in vivo. Our group has also identified that mice
lacking AGT or AT2 were protected from high-fat-diet-
induced obesity and featured adipose tissue hypotrophy.9,10
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Reports by Kouyama et al.,11 subsequently revealed that mice
lacking AT1 were also protected from diet-induced obesity,
revealing a synergistic contribution of AT1 and AT2 in
mediating the in vivo effect of Ang II on adipose tissue
development. In contrast to AT1 and AT2 knockout mice,
mice lacking the Mas receptor exhibited increased abdominal
fat mass associated with higher adipose tissue AGT expres-
sion, thereby suggesting a tight regulation of Ang II
production by Ang(1–7) in adipose tissue.12 Recently, studies
using knockout mice for renin (with reduction of both Ang II
and Ang(1–7) formation) or ACE confirmed that blocking
Ang II production in turn prevented fat mass enlarge-
ment.13,14 Similar findings were observed through the use of
RAS blockade.15–17 Together these findings showed an
important role for Ang II in the pathogenesis of obesity in
rodents.
RAS and energy homeostasis
The reduced fat mass in the aforementioned RAS knockout
mouse models was not associated with overall changes in
food intake.9–14 Attempts have been made to establish a link
between fat mass and intestinal lipid absorption among the
different RAS models. Although Takahashi et al. showed that
renin-deficient mice exhibited elevated gastrointestinal loss
of dietary fat,13 we and others were not able to find any
difference in lipid absorption in AGT or ACE knockout
mice.9,14 By contrast, it is clear that all RAS knockout mouse
models tested to date show a higher metabolic rate.9–14 We
previously reported that this increased energy expenditure
was the consequence of an increased locomotor activity
and whole-body lipid oxidation in AGT- and AT2-deficient
mice.9,10 These findings could be related in part to the
regulatory effect of Ang II on adiponectin secretion, which
controls muscle fatty acid oxidation capacity.18,19 Together,
these studies suggest that reduced Ang II signaling protects
fat mass enlargement in mice by increasing peripheral energy
expenditure and whole-body lipid oxidation.
AUTOCRINE ROLE OF THE RAS IN THE REGULATION OF
FAT MASS
Role of Ang II in preadipocyte differentiation
Conflicting data exist about the role of Ang II in preadipocyte
differentiation in vitro,3,20–22 and little is known about the
expression and regulation of AT1, AT2, and MasR in cultured
preadipocytes. Because AT2 mRNA expression is known to
be under the control of various growth hormones,23,24 it
is possible that the use of dissimilar conditioned media,
containing different growth hormones, may account for the
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Figure 1 | Formation of angiotensin peptides and roles of AT1 and AT2 receptors in lipid storage capacity of adipocytes.
ACE, angiotensin-converting enzyme; AGT, angiotensinogen; Ang, angiotensin; ATGL, adipose triglyceride lipase; Glut, glucose transporter;
HSL, hormone-sensitive lipase.
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discrepancies between in vitro studies. We recently showed
that overexpression of AGT in mice led to a slight decrease in
adipose cell number revealing an inhibitory effect of Ang II
on preadipocyte differentiation in vivo.25 This effect may
be explained by a direct action of Ang II on the proliferation
and differentiation of adipose tissue precursors,4,26 and the
consequence of an imbalance between AT1 and AT2.22,25
However, despite the reduced adipose cell number, local
production of AGT in adipose tissue clearly promotes fat
mass enlargement and thus, a role of Ang II in favoring
adipocyte metabolism appears to be the main factor
contributing to the expansion of the adipose tissue in vivo.
Role of Ang II in adipocyte metabolism
There are now several pieces of evidence that Ang II has a
major role in promoting lipid storage in mature adipocytes
by acting at two distinct levels. First, Ang II functions as a
lipogenic hormone through AT2 in both human and murine
adipocytes.27 Mice lacking AT2 revealed lower glucose uptake
in their adipose tissue following Ang II or insulin stimulation
(Figure 1).10,28 We also reported that Ang II increased the
storage of cholesterol in murine adipocytes through a PI3K-
dependent translocation of scavenger receptor type BI-
mediated cholesterol uptake.29,30 The inhibitory effect of
Ang II on apoE secretion could also contribute to the
increased cholesterol stores,31 by reducing the efflux of
cholesterol from adipocytes.32 Ang II also functions as an
antilipolytic hormone through AT1 in both human and
murine adipocytes (Figure 1).33–35 In vivo, mice treated with
valsartan, an AT1 antagonist, showed enhanced plasma free
fatty acid in response to fasting.36 The molecular mechanisms
of this effect has not yet been identified, but one explanation
is that Ang II may function on G protein or PI3K–Akt
signaling pathways.37 It is also possible that RAS enhances
lipid storage by other indirect mechanisms including reduc-
tion of adipose tissue blood flow or enhanced bradykinin
production by ACE-mediated sensitization of the insulin
pathway.38,39 Together these findings suggest that Ang II has
evolved different strategies to permit the storage of lipids in
mature adipocytes.
Role of Ang II in adipose tissue inflammation and remodeling
Growing evidence indicates that obesity involves a low-grade
inflammatory process and that inflammation has a significant
role in the onset of obesity.40 We recently observed an
increased expression of a variety of angiogenic and
inflammatory cytokines in adipose tissue of mice over-
expressing adipose AGT.25 This may contribute to local
insulin resistance, remodeling of adipose tissue vasculature
(angiogenesis),41 and infiltration of newly circulating im-
mune cells that are known to prevent preadipocyte
differentiation and further mediate vasoconstriction.42–44
Ang II promotes the release of these proinflammatory
cytokines from both mature adipocytes and preadipocytes
through activation of the NF-kB pathway.45,46 Ang II may
also function on stromal vascular immune cells, such as
monocytes, macrophages, and T cells, that are known to
express local RAS.47 The contribution of AT1 and AT2 on these
proinflammatory effects is not fully understood. Although
deletion of AT2 reduced inflammation observed in the adipose
tissue of transgenic mice overexpressing adipose AGT,25
administration of an AT1 receptor antagonist to obese KK-Ay
mice also reduced the expression of several proinflammatory
cytokines in adipose tissue.48 Further studies should help clarify
whether Ang II may modulate the NF-kB pathway through
direct AT1 or AT2 signaling or alternatively through enhanced
Toll-like receptor signaling secondary to modulation of free
fatty acid and cholesterol homeostasis.49,50
PARACRINE ROLE OF THE aRAS IN METABOLIC AND
INFLAMMATORY DISEASES
AGT mRNA abundance in adipose tissue may represent 60%
of that in liver,51 and contribute to approximately 30% of
circulating AGT levels in rodents.2 Under genetic or diet-
induced obesity conditions, adipocytes show increased aRAS
activity, an effect that is not observed in liver.6,7 Enhanced
AGT mRNA expression is also observed in visceral and
subcutaneous adipose tissue of obese patients.8,52 This
suggests that under pathophysiological conditions, enhanced
adipose tissue AGT secretion may contribute to metabolic
disorders associated with obesity (Figure 2).
aRAS and blood pressure
Early reports revealed a positive relationship between obesity,
plasma AGT levels, and hypertension.53,54 The first demon-
stration of a key endocrine role of adipose tissue AGT in
obesity-related hypertension was obtained using transgenic
mice with overexpression of AGT in adipose tissue. These
mice exhibited an increased fat mass and developed high
blood pressure.2,25 Part of the hypertensive action of aRAS
was the consequence of a dialogue between the adipose tissue
and kidney as evidenced by the fact that overexpression of
adipose AGT completely reversed the increased urine output
observed in AGT-deficient mice along with the rescue of the
morphological kidney abnormalities of AGT-deficient mice.2
The counter-regulatory interactions of AT1 and AT2 in the
cardiovascular and renal systems during the regulation of
blood pressure have been widely studied,55 but not in the
context of obesity with adipose overproduction of AGT. We
recently reported that adipose AGT overexpression increased
the vasopressor response of AT2-deficient mice and similarly
to Ang II infusion,56 part of this phenotype was to the
consequence of an increased renin synthesis in the kidney of
these mice.25 Modulation of plasma leptin levels in these
mice25 may also have contributed in part to the regulation of
blood pressure at the level of the central nervous system,57 by
modulating the response of b-adrenergic on renin activity.58
Together, these data reveal that aRAS is able to extend its
physiologic action beyond the local adipose tissue environ-
ment contributing to a better understanding of the mechan-
isms underlying the development of hypertension associated
with obesity.
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aRAS and insulin resistance
Although acute infusion of Ang II has been reported to
improve insulin sensitivity in both rats and humans,59–61
chronic infusion of Ang II leads to an oxidative stress-
mediated insulin resistance.37,62 Obesity with excessive
production of AGT in adipose tissue may represent such a
pathophysiological condition given that mice overexpressing
adipose AGT showed reduced insulin sensitivity as estimated
by the homeostasis model assessment index (unpublished
data). Interestingly, the metabolic effects of Ang II are
independent of its hypertensive and hemodynamic effects as
hydralazine normalized hypertension induced by Ang II
independently of any effect on fat mass.63 In addition, low-
dose RAS blockade promotes metabolic changes without
decreases in blood pressure in rodent models.28 The
beneficial effects of RAS blockade on oxidative stress and
insulin sensitivity37,48,64,65 could be secondary to reduced fat
storage,15–17 similar to that observed in mice lacking AT1 or
AT2.10,11 In humans, although short-term treatment with
RAS blockade (2 weeks) did not appear to have major effect
on insulin sensitivity,66,67 two meta-analyses suggested that
long-term treatment (44 years) with AT1 receptor blockers
or ACE inhibitors improved insulin sensitivity and decreased
the clinical onset of diabetes.68,69 Recently, the Navigator trial
revealed an impressive 14% reduction in the incidence of
diabetes after 5 years of treatment with an AT1 antagonist
(valsartan).70 Whether these differences may be attributed to
reduced body weight and fat mass in the long-term studies
will remain to be carefully investigated. At least, early reports
suggested beneficial effects of ACE inhibitors on body weight
and dyslipidemia in patients with essential hypertension
or non-insulin-dependent diabetes mellitus.71,72 Recently,
Shimabukuro et al.,73 showed that telmisartan (AT1 antago-
nists) was efficient at reducing the visceral fat area and
metabolic aberrations observed in patients with the meta-
bolic syndrome, raising the possibility that the beneficial
effect of RAS inhibition on insulin sensitivity may be
secondary to an effect on fat mass in humans. Together
these findings strongly support a role of aRAS in the
association between obesity and insulin resistance.
aRAS and other inflammatory diseases
Obesity is now recognized as a low-grade inflammatory
disease with consequences not only on lipid disorders, blood
pressure, and insulin resistance but also on other inflam-
matory diseases including atherosclerosis, inflammatory lung
disease, renal failure, and cancer.74–76 Interestingly, all these
pathologies have also been linked to immune disorders,44,77,78
in which Ang II may be an important actor.44,78,79 Recently,
two elegant studies have consecutively shown that Ang II
promotes the differentiation of monocytes from hematopoietic
progenitors80 and influences their chemotaxis potentially
through an upregulation of CCR2.81 These mechanisms could
contribute to an increased recruitment of immune cells in
site of inflammation as it has been shown in a context of
atherosclerosis.82 Thus, prolonged exposure to Ang II, as it
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Figure 2 |Hypothesis: influence of Ang II in the pathogenesis of metabolic syndrome. Fat cell hypertrophy is associated with
increased secretion of angiotensin precursor (AGT) and inflammatory cytokines. Ang II shows pleiotropic effect that could contribute to the
onset of insulin resistance, low-grade inflammation, hypertension, and atherosclerosis. FFA, free fatty acid.
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may occur in the setting of obesity with increased production
of AGT by adipose tissue, may be a key event in the
development of chronic inflammatory disorders by increasing
not only local inflammation but also by promoting the
infiltration of newly produced monocytes. Consistent
with this idea, lack of bone marrow CCR2 prevented
the development of atherosclerosis induced by Ang II,83 and
transplantation of renin/ bone marrow profoundly reduced
the atherosclerosis development of Ldlr/ recipient mice.84
Ang II has also been reported to be involved in renal
dysfunction through CCR2-mediated kidney monocyte infil-
tration and reduced glomerular filtration.85 The role of AT1
in mediating these effects is controversial,78,82,86,87 and further
work will be needed to elucidate carefully the balance
between AT1 and AT2 in mediating the effect of Ang II on
the immune and inflammatory responses.19,88 Together,
these findings suggest that lowering Ang II levels may be an
important therapeutic approach not only for hypertension and
insulin resistance but also for a broad range of inflam-
matory diseases, possibly including atherosclerosis and chronic
kidney disease.
SUMMARY AND FUTURE DIRECTIONS
The studies of mice and cells with genetic deficiencies of AT1
and AT2 have helped clarify the roles of these receptors in
adipose tissue lipid storage capacity, insulin sensitivity, blood
pressure, oxidative stress, and cholesterol homeostasis, all of
them contributing to the metabolic syndrome. In the future
studies, the generation of cell-specific knockouts of AT1 and
AT2 should help to clarify the importance of different local
RAS in the onset of obesity and obesity-associated diseases
and the underlying cellular mechanisms.
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